Interestingly, this patient responded better to chemotherapy and radiotherapy, challenging the notion that EML4-NTRK3 fusion invariably indicates a poor CFS prognosis (Tannenbaum-Dvir et al., 2015). This evidence concerns the gene NTRK3 and myalgic encephalomeyelitis/chronic fatigue syndrome.